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A TVo-Site Immunoradiometric Assay for Serum Calcitonin Using
Monoclonal Anti-Peptide Antibodies
Philippe Motte,* Malika Ait-Abdellah, Pascal Vauzelle, Paule Gardet, Claude Bohuon,
and Dominique Beliet

We have produced a library of monoclonal antibodies of various affinities by immunizing mice with
synthetic calcitonin (CT) 1-32. These monoclonal antibodies defined two antigenic determinants on
the molecule ofCT. Thefirstwas located in the 11-17 region of the hormone: the second was present on
the 26-32 portion of CT. The C-terminal epitope was restricted to the mature form ofthe hormone and
immunologically silent on synthetic peptides with sequences analogous lo the biosynthetic precursors
forCT. Using two high-ajfinity monoclonal antibodies, designated as CT07 and CT08, we developed a
two-site immunoradiometric assay (m-lRMA) for serum CT. This m-lRMA provided a sensitivity of 10
pg/mL using a one-step overnight incubation at room lemperature. Gel filtration analyses of serum
samples from patients with medullary thyroid carcinoma (MTC) demonstrated that the CT07-CT08
m-lRMA was specific for the circulating mature form of CT. (Henry Ford Hosp Med J 1987;35:
129-32)

S

ince the discovery that medullary thyroid carcinoma (MTC)
is a calcitonin (CT)-secreting tumor (1,2), numerous radioimmunoassays (RIAs) have been described for the measurement of CT in the serum (3,4). Heretofore, these RIAs were
based on the use of polyclonal antisera. Obtaining an anti-CT
antisemm is dependent on the stmcture of CT: a disulfide bridge
links amino acids one and seven. Five out of these first seven
amino acids are hydrophobic (Cys, Gly, Asn, Leu, and Cys),
and this sequence is engaged in a ring of constrained conformation (5). This conjunction defines a region of poor immunogenic
potential (6,7) and the production of antibodies directed against
the 1-10 sequence has not been reported. In contrast, polyclonal
antisera raised against synthetic CT recognize epitopes present
on the 11-32 region of CT, Various groups have disagreed about
normal immunoreactive CT levels in serum because the different immunoreactive species of CT present in the circulation
are variably recognized by different CT assays (4). The selective measurement of monomeric CT was only possible using
extraction-concentration methods (8) that remain difficult for a
routine purpose.
The hybridoma technology (9) allows the production of
monoclonal antibodies of particular interest in the constmction
of sensitive (10) and specific (11) immunoassays for tumor-associated antigens. To improve the detection methods for serum
CT, we investigated the potential of monoclonal anti-CT antibodies for the constmction of immunoassays for this molecule.

fragments of pro-CT were assembled by the solid phase method
(12) using an Applied Biosystems (Foster City, CA) model
430A peptide synthesizer. The purity of these peptides was
checked by reverse-phase, high-pressure liquid chromatography; amino acid composition was determined using amino acid
analysis and/or fast atom bombardment spectrometry, Amino
acid sequences of these peptides are depicted in Table 1. CT was
conjugated to tetanus toxoid (TT) using glutaraldehyde as a
coupling agent.

Production, selection, and characterization of monoclonal
anti-CT antibodies
High-responder mice (13) were immunized with the CT-TT
conjugate according to a previously described protocol (14). The
mice received four injections consisting of 15 p,g peptide each
during a schedule of up to 90 weeks. Three days after the last
intravenous injection of the conjugate, the splenocytes of the
mice were fused with the myeloma cell line NS I according to
previously described experimental procedures (15). The supernatants of growing hybridoma cells were screened for anti-CT
antibody production using a previously described (16) ELISA
system with CT-coated immunotitration plates as a solid phase.
Positive cells were cloned twice by limiting dilution and expanded in nude mice. Monoclonal antibodies were purified from
ascites fluid using protein-A sepharose (Pharmacia, Uppsala,

Methods
Synthetic peptides and immunogen
Synthetic human 1-32 CT was a gift from Drs. Scheibli and
Andreatta (Ciba-Geigy, Basel, Switzeriand). Synthetic peptides
corresponding to various fragments of tbis hormone or to
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Table 1
Amino Acid Sequences of the CT-Related Synthetic
Peptides Used in This Study: One Letter Code Was Used
CT 1-32
CT 1-10
CT 11-23
CT 17-32
CT 24-32
CT 26-32
PQN-34
PTN-47

CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP
CGNLSTCMLG
TYTQDFNKFHTFP
NKFHTFPQTAIGVGAP
QTAIGVGAP
AIGVGAP
QTAIGVGAPGKKRDMSSDLERDHRPHVSMPQNAN
^TYTQDFNKFHTFPQTAIGVGAPGKKRDMSSDLERDHRPHVSMPQNAN

Sweden) affinity chromatography (17). The isotype of monoclonal antibodies was determined as previously described
(17). Epitope mapping of monoclonal anti-CT antibodies
was performed using both 1) direct binding ELISAs with CT-,
PQN-34, and PTN-47 coated plates; and 2) hapten inhibition experiments in which the residual anti-CT activity of a monoclonal
antibody preincubated with various synthetic peptides was
measured by ELISA (18),
The affinity constant of monoclonal anti-CT antibodies was
calculated from RIA binding results using '-'I-CT (19) according to the method described by Van Heyningen et al (20),
TVo-site immunoradiometric assay for CT
A two-site immunoradiometric assay for CT was developed as
a "one step" simultaneous sandwich. A "capture" solid phase
was prepared by incubating polystyrene beads (Precision Plastic
Balls, Chicago, IL) with a 1:500 dilution of CT07-containing
ascites fluid in phosphate buffer solution (PBS) pH 7,4. Radiolabeled indicator antibody was prepared by radioiodination of
purified monoclonal antibody CT08 using the lodogen reagent
(21). Antibody-coated solid phase, CT-containing semm sample
(200 |JLL), and radiolabeled indicator antibody (100,000 cpm as
50 |JLL in PBS) were simultaneously incubated ovemight at room
temperature. The beads were then washed with distilled water
and bound radioactivity was measured in a gamma counter.
Results were expressed as a signal-to-noise (S/N) ratio where
noise was the mean cpm of negative controls run in the
same experiment,
Immunoreactive profile in serum
Serum from patients with MTC was passed through a
Sephadex G75 column equilibrated and eluted with a 0.1 M

Table 2
Immunochemical Characteristics of Six Monoclonal
Anti-CT Antibodies
Monoclonal
Antibody

Isotope

Affinity
Constant
(M-')

CTOl
CT02
CT03
CT06
CT07
CT08

ND*
IgG,
5,8 X 10»
IgG,
2,0 X 10"
IgG,
1,1 X 10'"
IgG,
0,9 X 10'°
IgG,
3,0 X lO'"
IgG,
*Not determined: CTOl did not bind to '^^i-CT.
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Antibody
Binding Site
CT
CT
CT
CT
CT
CT

11-17
26-32
26-32
11-17
26-32
11-17

PBS, pH 7.4, containing 10 mM sodium acetate, 10 mM barbital
and 0.1% sodium azide. Collected fractions were assayed using
the CT07-CT08 assay. In some experiments, guanidine and/
or dithiotreitol denaturation of eluates was performed according to the method extensively described by Goltzman and
Tischler (22). The resulting products were again analyzed by gel
filtration chromatography.

Results
A library of monoclonal anti-CT antibodies was produced.
Among 178 culture supematants positive for anti-CT antibody,
six were selected that displayed a significant binding at a high
dilution of supernatant in the ELISA system. The immunochemical characteristics of these antibodies are shown in Table
2. Hapten-inhibition experiments demonstrated that these antibodies bound to two antigenic regions on the molecule of CT
(14). CTOl, CT06, and CT08 monoclonal antibodies recognized
an epitope located in the 11-17 portion of CT; CT02, CT03, and
CT07 monoclonal antibodies recognized an antigenic determinant present in the 26-32 region of the hormone. The accessibility of these two epitopes on the biosynthetic precursors
of the hormone was studied by both direct binding assay (Table
3) and hapten-inhibition experiments using synthetic peptides
with sequence mimicking the C-terminus of pro-CT. The results
of such experiments have been extensively reported elsewhere
(18), Whereas the 11-17 antigenic determinant was found to be
accessible on both the mature form of the hormone and biosynthetic precursors, the 26-32 epitope was found to be only
expressed on the mature form of CT, ie, the 32 amino acid polypeptide bearing a proline amide as the C-terminal residue. Indeed, the binding of the CT02, CT03, and CT07 monoclonal

Table 3
Binding of Anti-CT Monoclonal Antibodies to Synthetic
Peptide-coated Plates in the ELISA System
Coated Peptide
Monoclonal
Antibody

CT 1-32

PQN-34

PTN-47

CT02
CT03
CT07
CT08

1,495
1,510
1,805
1.950

< 0.010
< 0.010
< 0.010
< 0.010

<
<
<

0.010
0.010
0.010
1.850

Results are expressed as absorbance at 492 nm after subtraction of the nonspecific
background. Monoclonal antibodies were tested at a 1:10^ dilution of culture supernatant.

Two-Site Immunoradiometric Assay—Motte et al

200

S/N
I

roo

lOOOpg/ml
500pg/ml

Fig 1—Schematic representation ofthe construction ofthe twosite monoclonal immunoradiometric assay for serum CT used in
this study.

antibodies to the 26-32 epitope was found to be dramatically dependent on the presence of the carboxamide group on the C-terminal proline residue. In the sequence of pro-CT, this residue is
bound via a peptide linkage to a glycine residue (23), and the Cterminal epitope is not accessible for antibody binding.
Using this library of monoclonal anti-CT antibodies directed
against two distinct epitopes to develop a multisite radioimmunoassay, we studied the ability of two monoclonal antibodies
to bind simultaneously to the molecule of CT. From these studies we concluded that the simultaneous binding of two monoclonal antibodies to CT was possible and mainly dependent on
the affinity constant of both the antibody used as a capture solidphase, and the antibody used as a radiolabeled indicator. These
data led us to use CT07 as a capture antibody and CT08 as a
radiolabeled indicator antibody in the development of a two-site
immunoradiometric assay for CT (Fig 1). The binding of '^^ICT08 to CT linked to the solid phase through CT07 was studied
at different temperatures. At 20°C, equilibrium was reached
after an 18-hour incubation (Fig 2). The limit of detection of the
assay was 10 pg/mL.
The profile of semm immunoreactive CT detected using the
CT07-CT08 m-IRMA was assessed by gel filtration analysis of
semm from MTC patients. A typical result is shown in Fig 3.
Several peaks of immunoreactivity were detected when analyzing the native semm; one corresponded to monomeric CT and
the other to higher molecular weight (HMW) species. The composition of these HMW species was studied using chemical denaturation. The fractions corresponding to the first peak (eluting
with the void volume of the column) were pooled (pool 1) and
denatured using the guanidine-dithiotreitol protocol; the fractions of intermediate molecular weight were pooled (pool 2) and
only submitted to the dithiotreitol denaturation. After these
treatments, immunoreactive CT eluted at the elution volume of
'"I-CT. These data establish that the different CT molecular
forms detected by the CT07-CT08 m-IRMA correspond to mature CT, to polymers of mature CT linked by disulfide bonds,
and to mature CT bound to irrelevant proteins. In conclusion,
1) the immunochemical characteristics of CT07 monoclonal
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Fig 2—Kinetics of binding ofthe monoclonal m-IRMA at room
temperature using various doses ofCT.

i
I
a.
o

a
a:
o
t~

o
-J

o

30

40

50

60

70

FRACTION NUMBER

Fig 3—Gel filtration analysis ofa serum sample from a patient
with MTC using the CT07-CT08 m-IRMA for CT. (m), immunoreactive profile ofthe native serum; (A), immunoreactive profile obtained after denaturation of pool I using the guanidine/
dithiotreitol protocol; (o), immunoreactive profile obtained
after denaturation of pool II using the dithiotreitol protocol.
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antibody, and 2) the data from gel filtration analysis of semm
samples led us to the conclusion that the CT07-CT08 based
m-IRMA is specific for the mature form of CT.

Discussion
The immunochemical heterogeneity of circulating CT has
hampered the standardization of semm CT levels among different laboratories. Indeed, various sequential-saturation radioimmunoassays differ in the immunochemical characteristics of the
polyclonal antiserum used in the construction of the assay,
resulting in various normal ranges for CT and multiple immunoreactive profiles in the semm. In an attempt to develop new
methods for both the measurement of CT and the diagnosis of
MTC, we have produced a library of monoclonal anti-CT antibodies. These antibodies of various affinity constants defined
two antigenic regions on human CT, one located in the intemal
sequence (11-17), and the other localized in the C-terminal region (26-32). By studying the molecular requirements for epitope-paratope binding, we found that the C-terminal epitope was
restricted to the mature form ofthe hormone. Then, monoclonal
antibodies directed against this epitope, particularly the high
affinity CT07 antibody, provided tools for the selective recognition of the mature CT in the circulation. A solid-phase immunoradiometric assay was developed using CT07 (anti-CT 26-32)
and CT08 (anti-CT 11-17) as capture antibody and indicator
antibody, respectively. Such an assay was found to be
sensitive (10 pg/mL), rapid (ovemight incubation), practicable
(one-step technique), and specific for the mature form of CT in
the semm. The clinical relevance of this assay has been studied
and the results showed that the m-IRMA allowed an earlier detection of either MTC or recurrence of the disease than did the
conventional antisemm-based radioimmunoassay (24).
Since successful treatment of MTC requires an early diagnosis,
reliable methods for the measurement of CT are of particular
importance. The monoclonal antibody-based immunoradiometric
assay described in this report may offer new insights in the diagnosis of this tumor.
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